Manson, Dr Alice J

Dr Alice MansonMBBS MRCP




Movement disorders

Training and education

  • Charing Cross and Westminster medical school.
  • Three years' general medical training.
  • Three years' research into Parkinson's disease at the Middlesex Hospital and National Hospital for Neurology and Neurosurgery.
  • One year additional neurophysiology training at the National Hospital for Neurology and Neurosurgery.
  • Neurology registrar training at Wessex Neurological Centre, Southampton General Hospital.


Dr Manson has worked for the Trust as a consultant since February 2006.

During her research and training she has gained extensive experience in the management of complex Parkinson’s disease, and acquired specific skills in EMG-guided botulinum toxin injections for complex dystonias.

Key achievements

  • Developing the movement disorders service.
  • Initiating the regional EMG-guided botulinum toxin injection service.
  • Developing local botulinum toxin injection services.
  • Facilitating a nurse-led apomorphine service.

Research (selected papers)

  • Manson AJ, Turner K, Lees AJ Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.Mov Disord. 2002 Nov;17(6):1235-41.
  • Manson AJ, Hanagasi H, Turner K, Patsalos PN, Carey P, Ratnaraj N, Lees AJ. Intravenous Apomorphine Therapy in Parkinson’s Disease - Clinical and Pharmacokinetic Observations. Brain 2001 Feb;124(Pt 2):331-40.
  • Manson AJ, Katzenschlager R, Hobart J, Lees A. High-dose Naltrexone for Levodopa-Induced-Dyskinesias. JNNP 2001 Apr;70(4):554-6.,
  • Manson AJ, Schrag A, Lees AJ. Low dose olanzapine for levodopa-induced dyskinesias in Parkinson’s disease. Neurology 2000;55(6):795-9 2006.
  • Katzenschlager R, Evans A Manson A et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. JNNP 2004;75(12):1672-7.
  • Giovannoni G, O'Sullivan J, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies.
  • J Neurol Neurosurg Psychiatry 2000;68:423-8
  • Manson AJ, Schrag, A. Levodopa-induced-dyskinesias: The clinical problem: Clinical features, incidence, risk factors, management and impact on quality of life. In: Bezard E, editor. Recent Breakthroughs in Basal Ganglia Research: Nova Publishing, 2006.